Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation therapy plus ipilimumab in melanoma with brain metastases
2013-001132-22Phase 2Completed
- Sponsor
- Gem
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma and brain metastases, sponsored by Gem. Primary endpoint: 1-year survival rate. Started Jan 2014; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on 2013-001132-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001132-22.